Clinical Trial Update: Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI) [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study evaluating an orally administered lyophilized fecal microbiota product for recurrent Clostridium difficile infection; study terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• PRIM-DJ2727

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Recurrent C. Difficile Infection | Phase 2 | Status: TERMINATED | Results posted: 2020-03-06